Conference Call Today July 17, 2025 at 4:30 PM Eastern Time / 3:30 PM Central Time DM199 Demonstrated Highly Statistically Significant and Clinically Meaningful Reductions in Systolic and Diastolic Blood Pressure for Combined Cohorts 6-9 DM199 Did Not Cross the Placental Barrier and was Generally Safe and Well Tolerated Highly Statistically Significant Reduction in Uterine Artery Pulsatility Index Robust Evidence Supports a... Read More

MINNEAPOLIS / Jun 24, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27. The Russell 3000 Index encompasses the 3,000 largest... Read More

MINNEAPOLIS / May 22, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will present at the upcoming Jefferies Global Healthcare Conference, being held in New York City, NY, June 3 – 5, 2025.... Read More

Company to Host Preeclampsia Key Opinion Leader Event May 28, 2025 at 8 AM Eastern / 7 AM Central MINNEAPOLIS / May 19, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, May 28, 2025, at 8:00 AM ET to provide further... Read More

MINNEAPOLIS / May 14, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today a poster presentation of the safety and clinical outcomes for ReMEDy2 study, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the 11 th European Stroke Organisation Conference – ESOC 2025 being... Read More

Conference Call and Webcast May 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Topline DM199 Preeclampsia Phase 2 Part 1A Proof of Concept Results Expected in Near Term and Phase 2 Part 1B Expected to Initiate in Q3 2025 KOL Event Scheduled for May 28, 2025 to Discuss the Disease of Preeclampsia and the Ongoing DM199 Phase 2 Study Design Acute Ischemic Stroke Phase 2/3 Program Enrollment Progressing as Planned Cash Runway... Read More

MINNEAPOLIS / May 08, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming investor conferences in May 2025. 2025 RBC Capital Markets Global Healthcare Conference Tuesday, May 20 th – Wednesday, May 21 st , 2025, in New York City, New York.... Read More

MINNEAPOLIS / May 07, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13 th . DiaMedica will host a live conference call on Wednesday, May 14 th at 7:00 AM Central... Read More

Conference Call and Webcast March 18 at 8:00 AM Eastern Time / 7:00 AM Central Time Preeclampsia Phase 2 Trial Preliminary Topline Safety and Efficacy Data from Part 1A of the Study Expected in the Second Quarter of 2025 Acute Ischemic Stroke Phase 2/3 Program Enrollment Ongoing Appointed Experienced Biotech Executive Daniel J. O’Connor to the Board Cash Runway into Q3 2026 MINNEAPOLIS / Mar 17, 2025 / Business Wire /... Read More

MINNEAPOLIS / Mar 11, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its full-year 2024 financial results will be released after the markets close on Monday, March 17 th . DiaMedica will host a live conference call on Tuesday, March 18 th at 7:00 AM Central Time to provide a... Read More

MINNEAPOLIS / Feb 24, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O’Connor to its Board of Directors, effective February 20, 2025. Mr. O’Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive... Read More

Scientific insight into DM199’s mechanism for increasing collateral circulation and salvaging brain tissue at-risk from infarction MINNEAPOLIS / Feb 20, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed publication entitled: Recombinant human tissue kallikrein-1... Read More

MINNEAPOLIS / Feb 10, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company’s management will present at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference on February 12 th , 2025 at 11:20am Eastern Time. Investors and attendees that would like to... Read More

MINNEAPOLIS / Dec 03, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, is excited to announce the formation of its Scientific Advisory Board (SAB) to support the development of DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia (PE). The members of the newly... Read More

Conference Call and Webcast Thursday November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Implemented Updates to AIS Program Intended to Enhance Probability of Trial Success and Expedite Study Completion, with Potential for a Reduced Study Size Preeclampsia Phase 2 Trial Received Regulatory Approval and First Patient Dosed Cash Runway Into Q3 2026 MINNEAPOLIS / Nov 13, 2024 / Business Wire / DiaMedica Therapeutics Inc.... Read More

MINNEAPOLIS / Nov 13, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that the first patient has been dosed in DiaMedica’s investigator-sponsored Phase 2 trial of DM199 for the treatment of preeclampsia (PE). DiaMedica anticipates top line data for Part 1A in the first half of... Read More

MINNEAPOLIS / Nov 12, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company’s management will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 in New York City, New York. Management will be available for one-on-one meetings... Read More

MINNEAPOLIS / Nov 06, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its third quarter 2024 financial results will be released after market close on Wednesday, November 13 th . DiaMedica will host a live conference call on Thursday, November 14 th at 7:00 AM Central Time to... Read More

Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025 MINNEAPOLIS / Oct 09, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced regulatory approval has been received to initiate a Phase 2 clinical... Read More

MINNEAPOLIS / Sep 04, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke and preeclampsia, announced today that management will be participating in the following investor conferences during September. HC Wainwright Global Investment Conference , September 9-11, New... Read More

Conference Call and Webcast August 8 at 8:00 AM Eastern Time / 7:00 AM Central Time Acute Ischemic Stroke (AIS) Phase 2/3 ReMEDy2 Trial Interim Enrollment (n=144) Targeted for Q1 2025 Preeclampsia Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 with Proof-of-Concept Results Targeted for First Half 2025 Completed $12 Million Private Placement, Extending Cash Runway Into Q3 2026 MINNEAPOLIS / Aug 07, 2024 / Business... Read More

MINNEAPOLIS / Aug 01, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2024 financial results will be released after the markets close on Wednesday, August 7 th . DiaMedica will host a live conference call on Thursday, August... Read More

Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central White Paper: The Potential of DM199 to Treat Preeclampsia MINNEAPOLIS / Jul 11, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced that it will host a virtual key opinion leader (KOL)... Read More

MINNEAPOLIS / Jul 01, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximately 4.7 million common shares at a purchase price of $2.50 per share, a premium of... Read More

MINNEAPOLIS / Jun 26, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. The transaction is expected to result in gross proceeds of $11.8 million. A placement... Read More

Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 Key Proof-of-Concept Results Expected in the First Half of 2025 Management will Host a Conference Call Thursday, June 27, 2024 at 8:00 AM Eastern Time / 7:00 AM Central Time to Discuss Preeclampsia Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 MINNEAPOLIS / Jun 26, 2024 / Business Wire / DiaMedica... Read More

Conference Call and Webcast May 9 at 8:00 AM Eastern Time / 7:00 AM Central Time First Patient Dosed in Relaunch of ReMEDy2 Stroke Trial Clinical Operations Team Expanded to Support Global Expansion $46.5 Million Cash with Runway to 2026 MINNEAPOLIS / May 08, 2024 / Business Wire / DiaMedica Therapeutics Inc . (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological... Read More

MINNEAPOLIS / May 02, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close on Wednesday, May 8 th . DiaMedica will host a live conference call on Thursday, May 9 th at... Read More

MINNEAPOLIS / Apr 17, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke. The company continues to work closely with... Read More

Conference Call and Webcast March 20 at 8:00 AM Eastern Time / 7:00 AM Central Time ReMEDy2 Clinical Site Activation Commenced in December 2023 Strengthened Management Team with Lorianne Masuoka, M.D., as Chief Medical Officer $53 Million Cash with Runway to 2026 MINNEAPOLIS / Mar 19, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel... Read More

DiaMedica Presents the Protocol and Rationale for ReMEDy2, a Pivotal Trial in Patients Suffering Acute Ischemic Stroke Ineligible for tPA and/or Mechanical Thrombectomy MINNEAPOLIS / Jan 29, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke (AIS), today announced a... Read More

Executive with Strong Track Record in Advancing Pipelines Through Clinical Development MINNEAPOLIS / Jan 22, 2024 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified... Read More

Conference Call and Webcast November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Updated Amendment to Phase 2/3 ReMEDy2 AIS Protocol Aimed at Enhancing Patient Enrollment and Increasing Probability of Study Success, 30-Day FDA Review Period Passed Without Comment ReMEDy2 Initial Activation of Clinical Sites Expected in November and December $56 Million Cash with Runway to 2026 MINNEAPOLIS / Nov 13, 2023 / Business Wire... Read More

MINNEAPOLIS / Nov 09, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, today announced that Rick Pauls, its President and CEO and Dave Wambeke, its Chief Business Officer will be participating in the 14th Annual Craig-Hallum Alpha Select Conference being held in New... Read More

MINNEAPOLIS / Nov 06, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its third quarter 2023 financial results will be released after the markets close on Monday, November 13 th . DiaMedica will host a live conference call on Tuesday, November... Read More

Dr. Shah Has Spent Over Two Decades Leading Biological Development Teams at Biotechnology Companies and Has Deep Expertise in Protein Development and Manufacturing MINNEAPOLIS / Sep 12, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of... Read More

MINNEAPOLIS / Sep 06, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7 th Annual Best Ideas Growth (BIG7) Conference in New York, on September 14, 2023. Management will conduct one-on-one... Read More

Conference Call and Webcast August 15 at 8:00 am Eastern Time / 7:00 am Central Time Company Resumes ReMEDy2 Clinical Trial after Clinical Hold Lifted Company Completed a $37.5M “At-The-Market” Private Placement, Cash Runway Into 2026 Company Completed an Additional Safety Cohort of ACEi Patients in its Phase 1C Healthy Volunteer Study MINNEAPOLIS / Aug 14, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a... Read More

MINNEAPOLIS / Aug 08, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2023 financial results will be released after the markets close on Monday, August 14 th . DiaMedica will host a live conference call on Tuesday, August 15... Read More

MINNEAPOLIS / Jul 18, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced the company will be attending the 2023 AAN Summer Conference on July 28-29, at the Minneapolis Hyatt Regency. This year’s conference will have a special focus on emergency and hospital neurology. The AAN Summer... Read More

MINNEAPOLIS / Jun 26, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the closing of its previously announced $37.5 million private placement to accredited investors. The Company sold approximately 11.0 million common shares a purchase price of $3.40 per share,... Read More

MINNEAPOLIS / Jun 21, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases (“DiaMedica” or the “Company”), today announced it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. The transaction is expected to result in... Read More

MINNEAPOLIS / Jun 21, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the... Read More

Recently Retired Medtronic Chief Medical Officer and Chief Scientific Officer with Deep Expertise in Stroke Treatment MINNEAPOLIS / May 30, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023. Dr. Richard... Read More

Conference Call and Webcast May 16 at 8:00 am Eastern Time / 7:00 am Central Time Company Completed In-Use Study, Results Support Proposed ReMEDy2 IV Dose Revision Company Completed a Phase 1C Study in Healthy Volunteers in Australia Affirming Proposed Revised DM199 IV Dose of 0.5 µg/kg for Continuing the ReMEDy2 Trial DiaMedica Plans to File Complete Clinical Hold Response This Week Cash Runway Into Q4 2024 MINNEAPOLIS /... Read More

MINNEAPOLIS / May 08, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2023 financial results will be released after the markets close on Monday, May 15 th . DiaMedica will host a live conference call on Tuesday, May 16 th at... Read More

In Conjunction with His Appointment, Mr. Wambeke Purchased $750,000 of Common Shares from DiaMedica in a Private Placement Priced Above Market MINNEAPOLIS / Apr 11, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David Wambeke, as Chief Business Officer... Read More

Conference Call and Webcast March 29 at 8:00 am Eastern Time / 7:00 am Central Time Company has had Ongoing and Successful Communications with the FDA to Address the Clinical Hold Company Completed Part 1 of In-Use Study, Results Support Proposed ReMEDy2 Dose Revision Cash Runway into Q4 2024 MINNEAPOLIS / Mar 28, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company... Read More

MINNEAPOLIS / Mar 20, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its full-year 2022 financial results will be released after the markets close on Tuesday, March 28 th . DiaMedica will host a live conference call on Wednesday, March 29 th... Read More

MINNEAPOLIS / Mar 13, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will present a corporate overview at the virtual Oppenheimer 33 rd Annual Healthcare Conference, which will take place March 13 th – 15 th , 2023. Mr.... Read More

MINNEAPOLIS / Mar 06, 2023 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Tanya Lewis to its board of directors effective March 1, 2023. Ms. Lewis, a recognized leader in the biopharma industry, brings over 25 years of experience in drug... Read More